Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence

被引:0
|
作者
Wang, Xiao-Xiao [1 ]
Song, Yu-Yun [1 ]
Jin, Rui [1 ]
Wang, Zi-Long [1 ]
Li, Xiao-He [1 ]
Yang, Qiang [2 ]
Teng, Xiao [3 ]
Liu, Fang-Fang [4 ]
Wu, Nan [1 ]
Xie, Yan-Di [1 ]
Rao, Hui-Ying [1 ]
Liu, Feng [1 ]
机构
[1] Peking Univ, Peoples Hosp, Beijing Int Cooperat Base Sci & Technol NAFLD Diag, Hepatol Inst,Infect Dis & Hepatol Ctr,Beijing Key, Beijing 100044, Peoples R China
[2] Hangzhou Choutu Technol Co Ltd, Hangzhou 310052, Peoples R China
[3] Histoindex Pte Ltd, Singapore 117674, Singapore
[4] Peking Univ, Peoples Hosp, Dept Pathol, Beijing 100044, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
non-alcoholic fatty liver disease; mouse models; steatosis; second-harmonic generation (SHG)/two-photon-excited fluorescence (TPEF); HIGH-FAT DIET; NONALCOHOLIC STEATOHEPATITIS; FEATURES;
D O I
10.3390/diagnostics14242889
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of fat in the liver, excluding excessive alcohol consumption and other known causes of liver injury. Animal models are often used to explore different pathogenic mechanisms and therapeutic targets of MASLD. The aim of this study is to apply an artificial intelligence (AI) system based on second-harmonic generation (SHG)/two-photon-excited fluorescence (TPEF) technology to automatically assess the dynamic patterns of hepatic steatosis in MASLD mouse models. Methods: We evaluated the characteristics of hepatic steatosis in mouse models of MASLD using AI analysis based on SHG/TPEF images. Six different models of MASLD were induced in C57BL/6 mice by feeding with a western or high-fat diet, with or without fructose in their drinking water, and/or by weekly injections of carbon tetrachloride. Results: Body weight, serum lipids, and liver enzyme markers increased at 8 and 16 weeks in each model compared to baseline. Steatosis grade showed a steady upward trend. However, the non-alcoholic steatohepatitis (NASH) Clinical Research Network (CRN) histological scoring method detected no significant difference between 8 and 16 weeks. In contrast, AI analysis was able to quantify dynamic changes in the area, number, and size of hepatic steatosis automatically and objectively, making it more suitable for preclinical MASLD animal experiments. Conclusions: AI recognition technology may be a new tool for the accurate diagnosis of steatosis in MASLD, providing a more precise and objective method for evaluating steatosis in preclinical murine MASLD models under various experimental and treatment conditions.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552
  • [42] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [43] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [44] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [45] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [46] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [47] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [48] IDENTIFICATION OF NEW EXOSOMAL MICRORNA MARKERS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE USING ARTIFICIAL INTELLIGENCE APPROACH
    Kohara, Michinori
    Kitab, Bouchra
    Komori, Atsumasa
    Tsukiyama-Kohara, Kyoko
    Ochiya, Takahiro
    Kimura, Masamichi
    Kimura, Kiminori
    Yatsuhashi, Hiroshi
    HEPATOLOGY, 2024, 80 : S613 - S613
  • [49] Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease
    Xu, Zhou
    Li, Hao
    Tian, Shen
    Wu, Juan
    Li, Xin
    Liu, Zi-li
    Li, Shu
    Chen, Yu-ling
    Xiao, Jun
    Wei, Jia-ying
    Liang, Xin-yu
    Ran, Liang
    Kong, Ling-quan
    JOURNAL OF HEPATOLOGY, 2020, 73 (05) : 1264 - 1265
  • [50] Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease
    Jamalinia, Mohamad
    Zare, Fatemeh
    Noorizadeh, Kiarash
    Lankarani, Kamran Bagheri
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (04) : 445 - 458